Advertisement

Cardinal Health receives $750,000 FDA grant to study oncology trial designs by comparing RWE to RCT results

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cardinal Health was awarded a $750,000 contract by FDA to implement an 18-month real world evidence study as part of the agency’s efforts to advance the applicability of RWE in regulatory decision-making.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

The field of surgical oncology has undergone transformative advancements over the last decade. From refining minimally invasive techniques to leveraging immunotherapy and viral oncolytics, our collective goal remains the same: improving patient outcomes while reducing treatment burden. At City of Hope, we have prioritized accelerating the translation of laboratory discoveries into clinical applications, and nowhere is this more evident than in our work with oncolytic viruses, remote surgery, and the integration of AI in surgical decision-making.
Advertisement
Advertisement